Market Overview

Acadia Pharmaceuticals Pops And Drops


Acadia Pharmaceuticals Inc. (NASDAQ: ACAD) shares were trading higher by $0.27 at $32.57 in Monday's session. Investors have decided to "sell the news" in the issue after the FDA recommenced approval of NUPLAZID.

After sprinting to $37 in after-hours trading upon the release of announcement, it quickly gave back those gains. By the open of the regular session, it was back to the $34 area and could only manage to make a high at $34.25 before sellers swarmed the issue.

So far, the ensuing decline has been taken beyond Friday's close, reaching $32.15, and is attempting to stage a rebound.

Posted-In: Technicals Intraday Update Movers Trading Ideas


Related Articles (ACAD)

View Comments and Join the Discussion!

Top Performing Industries For May 2, 2016

Bank Of America Highlights 'A Number Of Positive Catalysts' For Microsoft In 2017